European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer

Stefan Cristian Stanel, Jan Sjöberg, Tomas Salmonson, Paolo Foggi, Mariapaola Caleno, Daniela Melchiorri, Iordanis Gravanis, Kyriaki Tzogani, Francesco Pignatti, Stefan Cristian Stanel, Jan Sjöberg, Tomas Salmonson, Paolo Foggi, Mariapaola Caleno, Daniela Melchiorri, Iordanis Gravanis, Kyriaki Tzogani, Francesco Pignatti

Abstract

On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer resistant to or progressive after an oxaliplatin-containing regimen. Aflibercept is a recombinant fusion protein which blocks the activation of vascular endothelial growth factor (VEGF) receptors and the proliferation of endothelial cells, acting as a soluble decoy receptor that binds to VEGF-A with higher affinity than its native receptors, as well as placental growth factor and VEGF-B. The use of aflibercept was studied in a randomised, double-blind, placebo-controlled phase III study, in patients with metastatic colorectal cancer (mCRC) who had previously been treated with an oxaliplatin-based treatment with or without prior bevacizumab. Aflibercept (n=612) was compared with placebo (n=614), both in combination with FOLFIRI (infusional fluorouracil, leucovorin and irinotecan). The primary endpoint of the study was overall survival (OS). The median OS in the intent-to-treat population was 13.5 months in subjects treated with aflibercept compared with 12.1 months for subjects in the control arm (stratified HR=0.817, 95% CI 0.714 to 0.935, stratified pvalue=0.0032). The frequency of adverse events was higher in the aflibercept arm compared with the placebo arm, reflecting the toxicity profile of anti-VEGF agents in combination with chemotherapy. This paper is based on the scientific review of the application leading to approval of aflibercept in the EU. The detailed scientific assessment report and product information for this product are available on the European Medicines Agency website (http://www.ema.europa.eu). Trial registration number NCT00561470, Results.

Keywords: Aflibercept; Approval; EMA; European Medicines Agency; Metastatic Colorectal Cancer; Zaltrap.

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Kaplan -Meier plot for Overall Survival, VELOUR study.

References

    1. Van Cutsem E, Cervantes A, Nordlinger B, et al. . ESMO Guidelines Working Group. Metastatic colorectal Cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii1–9.10.1093/annonc/mdu260
    1. Tournigand C, André T, Achille E, et al. . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal Cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–37.10.1200/JCO.2004.05.113
    1. Goldberg RM, Sargent DJ, Morton RF, et al. . A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.10.1200/JCO.2004.09.046
    1. Hurwitz H, Fehrenbacher L, Novotny W, et al. . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.10.1056/NEJMoa032691
    1. Giantonio BJ, Catalano PJ, Meropol NJ, et al. . Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal Cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 2007;25:1539–44.10.1200/JCO.2006.09.6305
    1. Wilke H, Glynne-Jones R, Thaler J, et al. . Cetuximab plus irinotecan in heavily pretreated metastatic colorectal Cancer progressing on irinotecan: mabel study. J Clin Oncol 2008;26:5335–43.10.1200/JCO.2008.16.3758
    1. Cunningham D, Humblet Y, Siena S, et al. . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal Cancer. N Engl J Med 2004;351:337–45.10.1056/NEJMoa033025
    1. Peeters M, Price TJ, Cervantes A, et al. . Randomized phase III study of Panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal Cancer. J Clin Oncol 2010;28:4706–13.10.1200/JCO.2009.27.6055
    1. Grothey A, Van Cutsem E, Sobrero A, et al. . CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal Cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303–12.10.1016/S0140-6736(12)61900-X
    1. Rudge JS, Holash J, Hylton D, et al. . VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007;104:18363–70.10.1073/pnas.0708865104
    1. Van Cutsem E, Tabernero J, Lakomy R, et al. . Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal Cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499–506.10.1200/JCO.2012.42.8201
    1. Bennouna J, Sastre J, Arnold D, et al. . ML18147 Study Investigators. Continuation of Bevacizumab after first progression in metastatic colorectal Cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29–37.10.1016/S1470-2045(12)70477-1
    1. Grothey A, Sugrue MM, Purdie DM, et al. . Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326–34.10.1200/JCO.2008.16.3212
    1. Kopetz S, Hoff PM, Morris JS, et al. . Phase II trial of infusional fluorouracil, irinotecan, and Bevacizumab for metastatic colorectal Cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28:453–9.10.1200/JCO.2009.24.8252
    1. Asghar U, Hawkes E, Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer 2010;9:274–81.10.3816/CCC.2010.n.040
    1. Folprecht G, Pericay C, Saunders MP, et al. . Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann Oncol 2016;27:1273–9.10.1093/annonc/mdw176

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する